A trial to investigate alferminogene tadenovec in patients with stable angina

Trial Profile

A trial to investigate alferminogene tadenovec in patients with stable angina

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2015

At a glance

  • Drugs Alferminogene-tadenovec (Primary)
  • Indications Angina pectoris; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms AGENT-2
  • Most Recent Events

    • 11 May 2015 Results published in an Angionetics media release.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top